CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss to 13.5 million yuan in the first half of 2025 from 225.4 million yuan a year prior, a Wednesday Hong Kong bourse filing said.
The vaccine manufacturer's loss per share was 0.05 yuan, narrower from 0.91 yuan in the year-ago period.
Revenue rose 31% to 374.1 million yuan from 285.4 million yuan in the first half of 2024.